CT 1530

Drug Profile

CT 1530

Alternative Names: CT-1530

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xilintai Pharmaceutical
  • Developer Centaurus Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 01 Apr 2017 Phase-I/II clinical trials in Chronic lymphocytic leukaemia, Waldenstrom's macroglobulinaemia and Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in China (unspecified route) (NCT02981745)
  • 12 Dec 2016 Preclinical trials in Chronic lymphocytic leukaemia in China (unspecified route)
  • 12 Dec 2016 Centaurus Biopharma plans a phase I/II trial for Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and Waldenstrom's macroglobulinemia (Monotherapy, Second-line therapy or greater) in China (NCT02981745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top